EGFR and non-small cell lung carcinoma: In addition, the tyrosine kinase activity of EGFR in NCI-H1975, HCC827, and A549 cells after ATO and/or gefitinib treatment was tested with a tyrosine kinase assay kit, and ATO exhibited a similar inhibition on the three NSCLC cell lines [21].